Q-omics provides the consensus-scored IL9 profile across patient tissues and cancer cell-line models. IL9 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IL9 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, IL9 RNA expression shows 6,737 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight KIRC, and KICH as cancer lineages where IL9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL9 survival associations across molecular data types. IL9 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL9 RNA expression–survival associations across cancer types. High IL9 expression shows unfavorable associations in STAD, DLBC and BLCA, but favorable associations in KIRC, BRCA and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IL9 RNA expression.
This table summarizes IL9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for IL9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL9 shows lower tumor expression in KICH and KIRP and higher tumor expression in LUSC and THCA. The KICH box plot shows higher IL9 RNA expression in normal versus tumor tissue (log2 FC = −0.150, t-test p < 0.001).
This table shows molecular features associated with IL9 in patient tissues and cancer cell lines. In patient samples, IL9 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LUNG_NSCLC_LUAD.
